HPT is a disorder of the parathyroid gland that is caused due to presence of excessive parathyroid hormone (PTH) in the bloodstream. An increase in the activity of parathyroid glands, due to intrinsic abnormal changes, causes alteration of the excretion of PTH, and is known as PHPT. However, an extrinsic abnormal change affecting calcium homoeostasis, which stimulates production of PTH, is known as SHPT. In THPT, a state of autonomous secretion of PTH usually occurs as a result of longstanding CKD.
To forecast the diagnosed prevalent cases of PHPT, total prevalent cases for SHPT, and diagnosed prevalent cases of THPT in the 7MM, epidemiologists conducted a thorough literature review to find country-specific sources that provided data for the above-mentioned segmentations of the general population in the 7MM. In order to improve the accuracy of the forecast diagnosed prevalent cases of PHPT, total prevalent cases for SHPT, and diagnosed prevalent cases of THPT, epidemiologists used studies that provided data based on uniform diagnostic criteria and disease definition for these parameters across the 7MM.
In the 7MM, epidemiologists forecast that the diagnosed prevalent cases of PHPT will increase from 2,055,167 cases in 2015 to 2,373,547 cases in 2025, at an Annual Growth Rate (AGR) of 1.55%. The US will have the highest number of cases of PHPT among the 7MM throughout the forecast period, while Japan will have the lowest. In the 7MM, GlobalData epidemiologists forecast that the total prevalent cases of SHPT will increase from 75,326,251 cases in 2015 to 85,592,876 cases in 2025, at an AGR of 1.36%.
– The Hyperparathyroidism (HPT) EpiCast Report provides an overview of the risk factors and global trends of HPT in the 7MM (US, France, Germany, Italy, Spain, UK, and Japan). It includes a 10-year epidemiological forecast for the diagnosed prevalent cases of primary HPT (PHPT), total prevalent cases for secondary HPT (SHPT) (including diagnosed and undiagnosed), and diagnosed prevalent cases of tertiary HPT (THPT), based on country-specific studies published in peer-reviewed journals. The diagnosed prevalent cases of PHPT and total prevalent cases of SHPT are further segmented by sex and age (ages 20 years and above), and the diagnosed prevalent cases of THPT are segmented by sex. GlobalData epidemiologists also provide prevalent cases of SHPT in the total chronic kidney disease (CKD) pre-dialysis prevalent population and also in the total CKD dialysis prevalent population in the 7MM for the forecast period.
– The hyperparathyroidism epidemiology report is written and developed by Masters- and PhD-level epidemiologists.
– The EpiCast Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 7MM.
Reasons to buy
The Hyperparathyroidism EpiCast report will allow you to –
– Develop business strategies by understanding the trends shaping and driving the global hyperparathyroidism market.
– Quantify patient populations in the global hyperparathyroidism market to improve product design, pricing, and launch plans.
– Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for hyperparathyroidism therapeutics in each of the markets covered.
– Understand comorbid population of CKD cases and hyperparathyroidism.
Table of Content: Key Points
1 Table of Contents 5
1.1 List of Tables 6
1.2 List of Figures 7
2 Epidemiology 8
2.1 Disease Background 8
2.2 Risk Factors and Comorbidities 9
2.3 Global Trends 10
2.3.1 Prevalence 11
2.4 Forecast Methodology 12
2.4.1 Sources Used 12
2.4.2 Forecast Assumptions and Methods 16
2.4.3 Sources Not Used 25
2.5 Epidemiological Forecast of HPT (2015-2025) 26
2.5.1 Diagnosed Prevalent Cases 26
2.5.2 Total Prevalent Cases of SHPT 32
2.5.3 Diagnosed Prevalent Cases of THPT 42
2.6 Discussion 45
2.6.1 Epidemiological Forecast Insight 45
2.6.2 Limitations of the Analysis 46
2.6.3 Strengths of the Analysis 47
3 Appendix 48
3.1 Bibliography 48
Partner Relations & Marketing Manager
Ph: +1-646-845-9349 (US)
Ph: +44 208 133 9349 (UK)
Get in touch: